• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Must read ! ‘The business card’ on LinkedIn

anonymous

Guest
So some Sun guy posts his business card in LinkedIn, talking about the quality of the paper.

Are you serious ?

Is that your ‘unique selling proposition’? I guess Sun buys heavier stock paper ( which seems unimaginable), bc they’re NOT putting that money in product, research, salaries or QUALITY CONTROL.

Shameful Dilip, just shameful!
 




So some Sun guy posts his business card in LinkedIn, talking about the quality of the paper.

Are you serious ?

Is that your ‘unique selling proposition’? I guess Sun buys heavier stock paper ( which seems unimaginable), bc they’re NOT putting that money in product, research, salaries or QUALITY CONTROL.

Shameful Dilip, just shameful!


Part of me said this can’t be true, it’s surprising, but not shocking. I saw the post and yeah, it was a derm rep. Sun cuts corners everywhere.

Stink bugs.